FGF1 and diabetic cardiomyopathy: Considering that the modified nm-aFGF only losses its mitogenetic effect, but preserves all other bio-effects such as anti-apoptosis effect and cardio-protection [7], nm-aFGF maybe a potential candidate for the therapeutic application against diabetic cardiomyopathy in clinics due to its lack of oncogenic potential.